Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

NCT ID: NCT04567329

Last Updated: 2024-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 620 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-18
• Study Completion Date: 2021-08-30

Brief Summary

The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

Conditions

Dry Eye Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

NOV03

100% perfluorohexyloctane 4 times daily (QID)

Group Type: EXPERIMENTAL

NOV03

Intervention Type: DRUG

100% perfluorohexyloctane

Saline solution

0.6% sodium chloride solution 4 times daily (QID)

Group Type: PLACEBO_COMPARATOR

Saline Solution

Intervention Type: DRUG

0.6% sodium chloride solution

Interventions

NOV03

100% perfluorohexyloctane

Intervention Type: DRUG

Saline Solution

0.6% sodium chloride solution

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Was at least 18 years of age at the time of consent.

2. Provided written informed consent.

3. Had a subject-reported history of DED in both eyes for at least 6 months prior to Visit 0.

4. Had a TFBUT ≤5 seconds at Visit 0 and Visit 1.

5. Had an OSDI score ≥25 at Visit 0 and Visit 1.

6. Had an unanesthetized Schirmer's test I score ≥5 mm at Visit 0 and Visit 1.

7. Had MGD defined as total MGD score ≥3 at Visit 0 and Visit 1 (secretion of 5 central glands on the lower eyelid was evaluated, and each was scored from 0-3: 0 = normal; 1 = thick/yellow, whitish, particulate; 2 = paste; 3 = none/occluded). Total score ranged from 0-15.

8. Had a tCFS score between 4 and 11 (ie, sum of inferior, superior, central, nasal, and temporal) according to the NEI scale at Visit 0 and Visit 1.

9. Had at least one eye (the same eye) that satisfied all criteria for 4, 6, 7, and 8 above at Visit 0 and Visit 1.

10. Was able and willing to follow instructions, including participation in all trial assessments and visits.

Exclusion Criteria

A subject was excluded from participating in the study if he or she met any of the following criteria:

1. Had been randomized in NVU-002 or NVU-003 study or had participated in the NVU-004 open-label extension (OLE) study.

2. Had any clinically significant ocular surface slit-lamp findings at Visit 0 and Visit 1 and/or in the opinion of the Investigator had any findings that may have interfered with trial parameters, including eye trauma or history of eye trauma or anterior membrane dystrophy.

3. Had a history of Stevens-Johnson syndrome.

4. Had active blepharitis or lid margin inflammation that required any topical antibiotics or topical steroids within last 30 days prior to Visit 0 or would have likely required such treatment during the trial. Any other lid margin therapy such as lid scrubs, lid wipes, warm compresses, systemic antibiotics (such as tetracyclines) and oral supplements for treatment of ocular conditions had to be stable within the last 30 days prior to Visit 1 and was to be maintained throughout the trial.

5. Had had a LipiFlow procedure, intense pulse light procedure or any kind of other procedure affecting meibomian glands within 6 months prior to Visit 1.

6. Had abnormal lid anatomy that caused incomplete eyelid closure, including entropion and ectropion, or floppy lid syndrome that exposed parts of the conjunctiva or impaired the blinking function of the eye.

7. Had received or removed a permanent punctum plug within 3 months (6 months for dissolvable punctum plugs) prior to Visit 1 or was expected to receive a punctum plug or removal of a punctum plug, or had a punctum plug expected to be dissolved during the trial.

8. Had DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (as with vitamin A deficiency).

9. Had an ocular or periocular malignancy.

10. Had a corneal epithelial defect or had significant confluent staining or filaments anywhere on the cornea.

11. Had a history of herpetic keratitis.

12. Had active ocular allergies or ocular allergies that were expected to be active during the trial period.

13. Was diagnosed with an active ocular or systemic infection (bacterial, viral, or fungal), including fever requiring treatment with antibiotics.

14. Had worn contact lenses within 1 month of Visit 0 or anticipated using contact lenses during the trial.

15. Had used any eye drops and/or TrueTearTM device (intranasal tear neurostimulator) within 24 hours before Visit 1.

16. Had undergone intraocular surgery or ocular laser surgery within the previous 6 months or had any planned ocular and/or lid surgeries over the trial period.

17. Was a family member living in the same household as another subject who was randomized into Study 904 or NVU-003 or participated in NVU-004 OLE.

18. Was a clinical site employee directly involved in the management, administration, or support of this trial or was an immediate family member of the same.

19. Was a woman who was pregnant, nursing or planning a pregnancy.

20. Was unwilling to submit to a urine pregnancy test at Visit 0, Visit 1 and Visit 4 (or early termination visit) if of childbearing potential. Non-childbearing potential was defined as a woman who was permanently sterilized (eg, had a hysterectomy or bilateral tubal ligation or bilateral oophorectomy) or was post-menopausal (without menses for 12 consecutive months).

21. Was a woman of childbearing potential who was not using an acceptable means of birth control; acceptable methods of contraception included: hormonal (oral, implantable, injectable, or transdermal contraceptives); mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom); intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence could have been regarded as an adequate method of birth control; however, if the subject became sexually active during the trial, she had to agree to use adequate birth control as defined above for the remainder of the trial.

22. Had an uncontrolled systemic disease in the opinion of the Investigator.

23. Had a known allergy and/or sensitivity to the investigational drug or saline components.

24. Had active ocular or periocular rosacea that in the judgement of the Investigator interfered with the trial (eg, clinically relevant lid induration).

25. Had a pterygium in any eye.

26. Was currently enrolled in an investigational drug or device study or had used an investigational drug or device within 60 days of Visit 1.

27. Had used any topical ocular steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 60 days prior to Visit 0.

28. Had used any oral medications known to cause ocular drying (eg, antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 0 or was expected to be unstable during the trial.

29. Had corrected VA worse than or equal to logarithm of the minimum angle of resolution (LogMAR), +0.7 as assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) charts in both eyes at Visit 0 and Visit 1.

30. Had a condition or was in a situation (including language barrier) that the Investigator felt put the subject at significant risk, may have confounded the trial results, or may have interfered significantly with the subject's participation in the trial.

31. Had a history of isotretinoin (eg, Accutane, Myorisan, Claravis, Amnesteem) use.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bausch & Lomb Incorporated

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel Donatello

Role: STUDY_DIRECTOR

Bausch & Lomb Incorporated

Locations

Bausch Site 206

Phoenix, Arizona, United States

Bausch Site 202

Garden Grove, California, United States

Bausch Site 221

Hemet, California, United States

Bausch Site 214

Inglewood, California, United States

Bausch Site 226

Murrieta, California, United States

Bausch Site 213

Santa Ana, California, United States

Bausch site 236

Westminster, California, United States

Bausch site 225

Grand Junction, Colorado, United States

Bausch Site 211

Delray Beach, Florida, United States

Bausch Site 204

Morrow, Georgia, United States

Bausch Site 209

Chicago, Illinois, United States

Bausch site 218

Hoffman Estates, Illinois, United States

Bausch Site 230

Overland Park, Kansas, United States

Bausch Site 207

Louisville, Kentucky, United States

Bausch Site 228

Havre de Grace, Maryland, United States

Bausch Site 231

Bloomington, Minnesota, United States

Bausch Site 229

St Louis, Missouri, United States

Bausch Site 224

St Louis, Missouri, United States

Bausch Site 217

Washington, Missouri, United States

Bausch Site 208

Rochester, New York, United States

Bausch Site 210

Asheville, North Carolina, United States

Bausch site 233

High Point, North Carolina, United States

Bausch site 232

Southern Pines, North Carolina, United States

Bausch Site 201

Cincinnati, Ohio, United States

Bausch Site 216

Cleveland, Ohio, United States

Bausch Site 223

Columbus, Ohio, United States

Bausch Site 215

Nashville, Tennessee, United States

Bausch site 235

Austin, Texas, United States

Bausch Site 219

Cedar Park, Texas, United States

Bausch Site 212

League City, Texas, United States

Bausch site 234

San Antonio, Texas, United States

Bausch Site 222

San Antonio, Texas, United States

Bausch Site 203

San Antonio, Texas, United States

Bausch Site 220

Norfolk, Virginia, United States

Bausch Site 227

Seattle, Washington, United States

Countries

United States

References

Fahmy AM, Harthan JS, Evans DG, Greiner JV, Tauber J, Sheppard JD, Krosser S, Vittitow JL. Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials. Front Ophthalmol (Lausanne). 2024 Nov 5;4:1452422. doi: 10.3389/fopht.2024.1452422. eCollection 2024.

Reference Type: DERIVED

PMID: 39564145 (View on PubMed)

Sheppard JD, Kurata F, Epitropoulos AT, Krosser S, Vittitow JL; MOJAVE Study Group. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. Am J Ophthalmol. 2023 Aug;252:265-274. doi: 10.1016/j.ajo.2023.03.008. Epub 2023 Mar 21.

Reference Type: DERIVED

PMID: 36948372 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

904

Identifier Type: -

Identifier Source: org_study_id